Latest research on Herceptin

A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*

Latest findings

The major Phase III trial in 469 c-erbB-2-positive patients comparing the best available standard therapy versus best plus Herceptin showed that the latter improved objective response rates by 54%, response duration by 58% and time to progression by 65%. [source, 2001]
Trastuzumab (Herceptin) is a recombinant humanized IgG1 monoclonal antibody directed against the extracellular domain of the human epidermal growth factor receptor type 2 (HER2; also known as ERBB2). [source, 2016]
The 594 patients who satisfied all the eligibility criteria were randomly assigned in a 1 : 1 ratio to two groups: one group received chemotherapy alone, Cisplatin (80 mg/m2) plus Fluorouracil (800 mg/m2, Qd × 5 days), or Capecitabine (1000 mg/m2, bid × 14 days); the other group received chemotherapy plus trastuzumab (Herceptin, F. [source, 2016]
Even though the anti-HER2 antibody (Herceptin, also known as trastuzumab) treatment has been successfully used to treat metastatic HER2 breast cancer, the de novo and/or acquired resistance is still a major issue with trastuzumab treatment [7,8,9]. [source, 2016]
Prof Dennis Slamon of the Herceptin UCLA Jonsson Comprehensive Cancer Centre, California, USA followed this talk seamlessly by talking about taking CDK4 inhibitors into clinic. [source, 2016]
He noted his experience of developing Herceptin, a drug that has taken HER-2 positive patients from the worst outcomes for breast cancer patients to some of the best. [source, 2016]
Cetuximab (Erbitux), trastuzumab (Herceptin), and panitumumab (Vectibix) were purchased from Merck (Whitehouse Station, NJ), Roche (Basel, Switzerland), and Amgen (Thousand Oaks, CA), respectively. [source, 2016]
The conjugation efficiency between bispecific antibody (Bis), Herceptin (Her), Erbitux (Erb), and both Herceptin and Erbitux (Erb+Her) with MnMEIO-CyTE777-mPEG NPs was determined by collecting unconjugated antibodies in the supernatant after centrifugal filtration of the antibody reaction mixture and measuring the concentration using NanoDrop ND-1000 UV-vis spectrometer. [source, 2016]
The variable domains of heavy (VH) and light (VL) chains of anti-EGFR (Erbitux) and anti-HER2/neu (Herceptin) were linked via (Gly4Ser)3 to form scFv (Erbitux) and scFv (Herceptin), respectively. [source, 2016]
The bispecific fragment was then generated by linking scFv (Erbitux) and scFv (Herceptin) with a flexible peptide linker, ASTGS, and cloned into the 5' region of the human IgG1 Fc in pFUSE-hIgG1e4-Fc vector to form an Fc-fusion construct (Fig. 1A). [source, 2016]